Abbott Vascular
Future Technologies

Turning Science into Caring

Abbott
A Promise for Life

Abbott Vascular Strategy

ESTABLISH a standard of care

LEAD with a broad portfolio



DELIVER game-changing technologies



Leader in Vascular Care

Pictures on file at Abbott Vascular.

Abbott Vascular

Broad Cardiovascular Product Portfolio

XIENCE PRIME*
Everolimus Eluting
Coronary Stent System

XIENCE V*
Everolimus Eluting
Coronary Stent System

MULTI-LINK VISION
Coronary Stent System

VOYAGER RX & OTW & VOYAGER NC*
Coronary Dilatation Catheters`

HI-TORQUE BALANCE MIDDLE WEIGHT UNIVERSAL II*
Frontline Guide Wire

MitraClip*
Percutaneous Mitral Repair

HI-TORQUE WHISPER ES
Finesse Guide Wire

* These products are currently CE marked. Where CE marking is not the registration in force, these products may be in Abbott Vascular's pipeline.

Abbott Vascular

Broad Peripheral Product Portfolio

Stents: Self-Expanding



Xpert .018

Absolute .035

Absolute Pro .035
and
Absolute Pro LL .035*

Stents: Balloon Expandable

RX Herculink
Plus .014

RX Herculink
Elite .014

Omnilink
.018/.035

Omnilink Elite .035

Note: These products are currently CE marked. Where CE marking is not the registration in force, these products may be in Abbott Vascular's pipeline.

Abbott Vascular

Broad Endovascular Product Portfolio



Fox Cross .035
PTA Catheters

Fox Plus .035
PTA Catheters

Fox sv .018
PTA Catheters

Viatrac 14 Plus .014
PTA Catheters

StarClose SE
Vascular Closure System

Prostar XL 24F
Suture-Mediated Large Hole Closure

Perclose ProGlide
Suture-Mediated Closure System

Note: These products are currently CE marked. Where CE marking is not the registration in force, these products may be in Abbott Vascular's pipeline.

Abbott Vascular

A Choice in Carotid Stent Systems …



Emboshield NAV6
Embolic Protection System



Xact
Carotid Stent System

RX Accunet
Embolic Protection System

RX Acculink
Carotid Stent System

Note: These products are currently CE marked. Where CE marking is not the registration in force, these products may be in Abbott Vascular's pipeline.

Abbott Vascular

Abbott Vascular Research Strategy: Relevant, Meaningful, Applied Technology



A Pipeline that Delivers

17 Programs in Development

	PROGRAMS IN DEVELOPMENT	EXAMPLE PROGRAMS	
 **DES**	2	▪ New Alloy DES	▪ XIENCE SBA
 **Bioresorbable Vascular Scaffold**	2	▪ Coronary Bioresorbable Vascular Scaffold	▪ Peripheral Bioresorbable Vascular Scaffold
 **Balloon Dilatation Catheters**	7	▪ VERSA TREK ▪ TREK / MINI TREK ▪ Fox sv (expanded matrix) ▪ .014 RX BTK BDC	▪ .014 RX Carotid/Renal BDC ▪ Next Gen .035 BDC ▪ Peripheral Drug Coated Balloon
 **Coronary Guide Wires**	2	▪ BMW Optimum	▪ Next Generation HI-TORQUE Frontline
 **Bare Metal Stents**	1	▪ New Alloy BMS	
 **Balloon Expandable Stents**	2	▪ Balloon Expandable Peripheral Stent	▪ Renal Stent
 **Self-Expanding Stents**	1	▪ Peripheral Self-Expanding Stent	

Note: Pipeline products currently in development at Abbott Vascular. Not available for sale.

Abbott Vascular

History of Investment in Clinical Trials to Advance Therapies

Vascular Access 2004-2006

- CLIP 2004: U.S. clinical trial evaluating the safety and efficacy of the StarClose closure device
- RISE 2006: Evaluation of a clip-based technology to investigate early ambulation with the StarClose SE closure device



PROSPECT 2004

- **P**roviding **R**egional **O**bservations to
- **S**tudy **P**redictors of **E**vents in the **C**oronary **T**ree

SPIRIT Family of Trials

- U.S. and International clinical trials for Everolimus Eluting Coronary Stent System
- SPIRIT PRIME: First patient enrolled on June 16, 2009



Carotid Family of Trials

- SECuRITY
- ARCHeR
- EXACT
- CAPTURE
- CAPTURE 2
- PROTECT
- CREST (NIH)
- ACT I
- CHOICE

ABSORB 2006-Present

- International FIM clinical trial for a fully Bioresorbable Everolimus Eluting Coronary Stent System
- Cohort B: First patient enrolled on March 19, 2009, incorporating device improvements from Cohort A



STRIDES 2007

- International FIM SFA clinical trial for Everolimus Eluting Self-Expanding Stent System

Note: Bioresorbable and Everolimus eluting self-expanding stents are currently in development at Abbott Vascular. Not available for sale. Pictures on file at Abbott Vascular.

Abbott Vascular

TREK Coronary Balloon Dilatation Catheter

Key Goals

- Ultra low crossing profile
  - ≤0.023″ for 3.0 mm
  - ≤0.021″ for 1.20 and 1.5 mm
- Optimized tip design
  - Most flexible tip; from soft tip to proximal balloon shoulder
  - Improved tip shape for crossing lesions
- Improved pushability and trackability
  - New balloon material and processing technologies
  - New chassis materials and construction for improved pushability and trackability



Note: Pipeline products. Currently in development at Abbott Vascular. Not available for sale. Pictures on file at Abbott Vascular.

Abbott Vascular

PROGRESS Family of Guide Wires for Chronic Total Occlusions

Key Goals

- Hybrid concept to optimize cross, torque, and tactile feel
  - Core-to-tip DURASTEEL core with transitionless grind for optimum torque
  - Lubricious coating for improved deliverability in tortuous anatomy and long lesions
  - Exposed tip coils for tactile feedback
  - Smaller tip profile to penetrate lesions

Note: This product has received regulatory approval in most countries. Please check with your local regulations.
All illustrations are artist's renditions.

Abbott Vascular

Abbott Vascular Stent History
Proven Platform Design

- Consistent pattern design – large body of clinical data
- MULTI-LINK VISION platform for XIENCE V[1]
- MULTI-LINK 8[2] is the technology platform for XIENCE PRIME[1]
- Our vision of stent development from MULTI-LINK to XIENCE PRIME to a bioresorbable device[2] focuses on the importance of strut thickness without compromising radial force, scaffolding, or radiopacity

1997 — Corrugated Ring and Link Design — Current

[1] These products are currently CE marked. Where CE marking is not the registration in force, these products may be in Abbott Vascular's pipeline.
[2] Pipeline product currently in development at Abbott Vascular. Not available for sale.

Abbott Vascular

XIENCE V:
The Foundation for Future Products







PRODUCT	DRUG/ DOSE	POLYMER/ RELEASE RATE	STENT MATERIAL	STENT DELIVERY SYSTEM (SDS)	STENT DESIGN
XIENCE V	Everolimus	Fluorinated Copolymer	Cobalt Chromium	ML VISION	ML VISION
XIENCE PRIME				NEW	NEW
New Alloy DES *			NEW	NEW	NEW
Bioresorbable Vascular Scaffold *		Polylactic Acid	Polylactic Acid	ML VISION	NEW

*Note: Pipeline products. Currently in development at Abbott Vascular. Not available for sale. Pictures on file at Abbott Vascular.

Abbott Vascular

Expanding Performance: XIENCE PRIME Based on Proven Technology Platform

Key Goals

- 38 mm designed to deliver like an 18 mm
- New stent design and stent delivery system for improved deliverability to complex anatomy
- Minimize injury outside of the stented area
- Short balloon tapers
- Full matrix of lengths and diameters (46 sizes vs. 36 for XIENCE V)

* Note: XIENCE PRIME is currently CE marked. Where CE marking is not the registration in force, this product may be in Abbott Vascular's pipeline.

* XIENCE PRIME is built on XIENCE V DES technology.

Abbott Vascular

XIENCE SBA: A DES Solution for Side Branch Access

Key Goals

- DES that maintains side branch access
- Redesigned MULTI-LINK FRONTIER concept
  - Single tip delivery
  - Dual balloon inflation
  - Side branch portal
- Stent and delivery system based on ML VISION system
- Same drug and polymer coating as XIENCE V[1]



[1] XIENCE V is currently CE marked. Please, check the regulatory status of XIENCE V before distribution in area where CE marking is not the registration in force.
Note: Pipeline products currently in development at Abbott Vascular. Not available for sale. All illustrations are artist's renditions.

Abbott Vascular

New Alloy BMS / DES

Key Goals

- Achieve Ultra-Thin Stent Struts Without Compromising
  - Radiopacity
  - Recoil
  - Strength
- Possible Benefits
  - Faster endothelialization observed in animal models
  - Less vessel injury observed in animal models
  - Better deliverability
- Multi-layer balloon technology for improved deliverability with flatter compliance



Note: Pipeline products currently in development at Abbott Vascular. Not available for sale. Pictures on file at Abbott Vascular.

Abbott Vascular

New Alloy Enables Much Thinner Stent Struts

Cypher	Taxus Liberte	Endeavor	XIENCE V	New Alloy Goal
				
Strut Thickness	Strut Thickness	Strut Thickness	Strut Thickness	Strut Thickness
.0055”/140μm	**.0038”/97μm**	**.0036”/91μm**	**.0032”/81μm**	**≤ .0027”/70μm**
Alloy	Alloy	Alloy	Alloy	Alloy
Stainless Steel	**Stainless Steel**	**Cobalt Nickel**	**Cobalt Chrome**	**New alloy**

3.0X18mm Stents, 500X Magnification. Photos taken by and on file at Abbott Vascular.

TAXUS Liberte is a registered trademark of Boston Scientific or its affiliates. Cypher is a registered trademark of Johnson and Johnson Inc. Endeavor is a registered trademark of Medtronic Corp. XIENCE V is a registered trademark of Abbott Group of Companies

Abbott Vascular

Making Bioresorbable Technology a Reality

Revolution One: Balloon Angioplasty (PTCA)

1977

Revolution Two: Bare Metal Stents (BMS)

1988

Revolution Three: Drug Eluting Stents (DES)

2001

Now, we are on the brink of Revolution Four: Bioresorbable Technology

2009

ABSORB

Key Goals

- Naturally resorbed, fully metabolized
- Excellent data from 2 year follow-up of first in man study
- 3+ year lead vs. competition

Note: Pipeline technology currently in development at Abbott Vascular.
Not available for sale. Pictures on file at Abbott Vascular.

Abbott Vascular

A Revolution in Interventional Cardiology
Bioresorbable Vascular Scaffold

Key Goals

- Naturally resorbed, fully metabolized
- Acutely perform like a metallic DES: deliverability, conformability, radial strength
- Long-term: restore vascular function, improved clinical outcomes, lower restenosis
- Compatible with CT imaging

Note: Pipeline products. Currently in development at Abbott Vascular. Not available for sale. Pictures on file at Abbott Vascular.

ABSORB Cohort A
3-Year Clinical Data

Status

- ABSORB Cohort A 3-Year Data:
  - One MACE* (NQMI); No additional MACE between 6 months and 3 years
  - No stent thrombosis through 3 years
  - Lumen enlargement from 6 months to 2 years by IVUS and OCT
  - Restoration of vasomotion – including the treated segment
  - Bioresorption of device

Note: Pipeline products. Currently in development at Abbott Vascular. Not available for sale. Pictures on file at Abbott Vascular.
*MACE is defined as a composite of cardiac death, myocardial infarction, and ischemia-driven target lesion revascularization
Sources: Serruys, PW, AHA 2009; Serruys, PW, et al, Lancet 2009; 373: 897-910

A Commitment to Innovation

Continuing to Innovate Based on the Superiority* of XIENCE V

Consistently Exploring the Next Generation DES

VRT

XIENCE V

2006



XIENCE PRIME

2009



XIENCE SBA**

Future

New Alloy DES**

Future

ABSORB**

Future

*Xience V has demonstrated statistical superiority against Taxus Express in the primary endpoints of SPIRIT IV, SPIRIT III, and SPIRIT II in target lesion failure, in-segment late loss, and in-stent late loss, respectively. Source: SPIRIT IV 1-year results, Gregg Stone. TCT 2009 and data on file at Abbott Vascular.

** Pipeline products currently in development at Abbott Vascular. Not available for sale.

Abbott Vascular

Mitral Valve Repair: MitraClip System

Key Goals

- To develop a catheter-based method to treat mitral regurgitation (MR)
- This method is designed to allow the valve to operate more efficiently while preserving surgical options
- To design solutions to meet unmet clinical needs in structural heart

Status:

- >1,000 patients treated; several years ahead of nearest device competitors
- CE mark (2008) with sales ongoing in Europe
- Completed enrollment and 1Y follow-up of US pivotal trial
- Continued access registry enrolling in the US
- Expected to be first product approved in the US

Market Conditions

- In the US & Europe, significant MR affects more than 8 million people, with more than 600,000 new diagnoses, but only 20% undergoing surgery each year



* Note: MitraClip is currently CE marked. Where CE marking is not the registration in force, this product may be in Abbott Vascular's pipeline.
Source: Thompson, Percutaneous Heart Valve Technology: The Mitral Challenge. Windhover Information Inc. (02/09).
Pictures on file at Abbott Vascular.

Abbott Vascular

Abbott Vascular Strategy

ESTABLISH a standard of care

LEAD with a broad portfolio



DELIVER game-changing technologies



Leader in Vascular Care

Pictures on file at Abbott Vascular.

Abbott Vascular

Established BMS Leadership: MULTI-LINK 8

Key Goals

- Outstanding Deliverability
  - Advanced MULTI-LINK design
  - Innovative new stent delivery system
- Clinically proven MULTI-LINK design
  - Built on 7 generations of market-leading stents
  - CE marked and indicated for AMI
- Available in lengths up to 38 mm
- Platform for XIENCE PRIME

Note: This product is currently CE marked. Please, check the regulatory status before distribution in area where CE marking is not the registration in force.

Abbott Vascular

Multi-Layer Balloon Technology

Key Goals

- Multi-layer balloons will be designed to overcome the trade-off between high pressure and flexibility.
- Data support multiple layers will offer greater strength with superb flexibility.



Next Generation Non-Compliant Balloons…
with higher pressure and the deliverability of today's frontline

Next Generation Frontline Balloons…
with best-in-class flexibility, deliverability and low profiles

Versatility Balloon…
highly deliverable for pre-dilatation with high pressures for post-dilatation

Next Generation Stent Delivery Systems…
with improved deliverability without compromising compliance

Note: Pipeline technology in some areas. Currently in development at Abbott Vascular. Not available for sale. Pictures on file at Abbott Vascular.

Abbott Vascular

Expanding Indications: XIENCE PRIME BTK

Key Goals

- Expanded indications of Everolimus eluting CoCr BES to include treatment of severe claudication or critical limb ischemia (CLI) due to infrapopliteal disease
- Extended length matrix to 38mm

* Note: XIENCE PRIME is currently CE marked. Where CE marking is not the registration in force, this product may be in Abbott Vascular's pipeline.
* * XIENCE PRIME is built on XIENCE V DES technology.

Abbott Vascular

Abbott Vascular's Commitment to Peripheral Balloon Dilatation Catheters (BDCs)

Key Goals

Next Gen .014 RX Carotid / Renal & OTW Below-the-Knee BDC

- Broad size matrices with best in class anatomy-specific features
- Advanced multi-layer technology for low crossing profile and excellent rewrap



Next Gen .035 BDC

- Broad size matrix with balloons up to 200mm
- Advancing multi-layer technology for low (<6F) crossing profile on most sizes

Note: Pipeline products. Currently in development at Abbott Vascular. Not available for sale. Pictures on file at Abbott Vascular.

Abbott Vascular

Absolute Pro & Absolute Pro LL Self-Expanding Peripheral Stent System

Key Goals

- Peripheral self expanding stent system offering best in class deliverability, deployment accuracy and stent fatigue resistance
- Absolute Pro LL utilizes proven Absolute stent pattern extended up to 180* mm in length
- Leverage I-Beam technology to enhance system deliverability and accuracy

Status:

- Available in stent lengths ≤ 150 mm

* Note: Pipeline product. 180 mm currently in development at Abbott Vascular. Not available for sale. Pictures on file at Abbott Vascular.

Abbott Vascular